7579 alpha/beta-Hydrolases
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Phenylpropanoids and polyketides | 28 | 9.1 | 3.07× | q < 0.0001 | |
| Benzenoids | 93 | 32.1 | 2.90× | q < 0.0001 | |
| Organosulfur compounds | 18 | 9.0 | 1.99× | q = 0.01 | |
| Homogeneous non-metal compounds | 164 | 94.4 | 1.74× | q < 0.0001 | |
| Organic acids and derivatives | 113 | 67.9 | 1.66× | q < 0.0001 | |
| Organic nitrogen compounds | 22 | 14.0 | 1.57× | q = 0.06 | |
| Organic oxygen compounds | 129 | 87.4 | 1.48× | q < 0.0001 | |
| Lipids and lipid-like molecules | 58 | 48.9 | 1.19× | q = 0.23 | |
| Organoheterocyclic compounds | 60 | 67.5 | 0.89× | q = 0.43 | |
| Homogeneous metal compounds | 164 | 215.4 | 0.76× | q < 0.0001 | |
| Mixed metal/non-metal compounds | 1 | 9.2 | 0.11× | q = 4.6e-3 | |
| Nucleosides, nucleotides, and analogues | 7 | 121.3 | 0.06× | q < 0.0001 | |
| Organophosphorus compounds | 7 | 0.2 | 47× | not tested | |
| Organometallic compounds | 4 | 0.6 | 6.40× | not tested | |
| Organohalogen compounds | 6 | 1.3 | 4.80× | not tested | |
| Organic 1,3-dipolar compounds | 1 | 0.4 | 2.73× | not tested | |
| Alkaloids and derivatives | 4 | 1.5 | 2.67× | not tested | |
| Organic salts | 1 | 0.5 | 2.19× | not tested | |
| Hydrocarbons | 3 | 3.1 | 0.98× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 1,034 |
| DB03721 | SIA | N-acetyl-alpha-neuraminic acid | 61 |
| DB02811 | DEP | Diethyl phosphonate | 50 |
| DB03793 | BEZ | Benzoic acid | 33 |
| DB01992 | COA | Coenzyme A | 31 |
| DB04417 | NPO | P-Nitrophenol | 25 |
| DB03313 | CSC | Cephalosporin C | 24 |
| DB09459 | TLA | L-tartaric acid | 22 |
| DB07767 | FER | Ferulic acid | 20 |
| DB00145 | GLY | Glycine | 19 |
| DB03297 | PMS | Benzylsulfonic acid | 19 |
| DB03796 | PLM | Palmitic Acid | 19 |
| DB14756 | SRT | meso-Tartaric acid | 17 |
| DB03345 | BME | Mercaptoethanol | 16 |
| DB00172 | PRO | Proline | 15 |
| DB03085 | GOA | Glycolic acid | 15 |
| DB03568 | BUA | Butyric Acid | 14 |
| DB07821 | GD7 | (1R)-1,2,2-trimethylpropyl (R)-methylphosphinate | 14 |
| DB02175 | MLA | Malonic acid | 13 |
| DB02226 | TZ4 | 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium | 13 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 1,006 |
| CL | CHLORIDE ION | 865 |
| CAmetal | CALCIUM ION | 433 |
| NAmetal | SODIUM ION | 244 |
| MGmetal | MAGNESIUM ION | 141 |
| ZNmetal | ZINC ION | 118 |
| P6G | HEXAETHYLENE GLYCOL | 114 |
| Kmetal | POTASSIUM ION | 82 |
| SIA | N-acetyl-alpha-neuraminic acid | 68 |
| DEP | DIETHYL PHOSPHONATE | 52 |
| BEZ | BENZOIC ACID | 40 |
| PG0 | 2-(2-METHOXYETHOXY)ETHANOL | 36 |
| HI6 | 4-(AMINOCARBONYL)-1-[({2-[(E)-(HYDROXYIMINO)METHYL]PYRIDINIUM-1-YL}METHOXY)METHYL]PYRIDINIUM | 34 |
| PMS | phenylmethanesulfonic acid | 33 |
| TLA | L(+)-TARTARIC ACID | 32 |
| 6NA | HEXANOIC ACID | 31 |
| COA | COENZYME A | 31 |
| TMO | trimethylamine oxide | 31 |
| CDmetal | CADMIUM ION | 30 |
| MRD | (4R)-2-METHYLPENTANE-2,4-DIOL | 30 |